Bernard J, Reveil B, Najman I, Liautaud-Roger F, Fouchard M, Picard O, Cattan A, Mabondzo A, Laverne S, Gallo R C
Institut Jean-Godinot, Reims, France.
AIDS Res Hum Retroviruses. 1990 Feb;6(2):243-9. doi: 10.1089/aid.1990.6.243.
Most attempts to produce a vaccine against HIV-1 infection are utilizing envelope protein components. Hypothetically such vaccine candidates could stimulate production of antibodies that enhance HIV-1 infection via the macrophage route of entry and, consequently, cannot be detected in the conventional neutralization assay. To study this hypothesis we report an assay designed to evaluate the protective/enhancing activity of serum from seropositive immunized or infected individuals. Highly purified activated FcR-bearing monocytes-macrophages were infected with HIV-1 in the presence of the sera, then washed and cocultured with activated peripheral blood mononuclear cells (PBMC) from a normal donor. Productive viral infection, as evaluated by p24 antigen semiquantitative assay in the culture supernatants, allow evaluation of protective/enhancing activity of the sera. The data clearly show that protective rather than enhancing activity is present in the serum of env protein-immunized individuals.
大多数研发抗HIV-1感染疫苗的尝试都在利用包膜蛋白成分。理论上,这类候选疫苗可能会刺激产生通过巨噬细胞进入途径增强HIV-1感染的抗体,因此在传统中和试验中无法检测到。为了研究这一假设,我们报告了一种旨在评估血清阳性免疫或感染个体血清的保护/增强活性测定方法。在血清存在的情况下,用HIV-1感染高度纯化的携带FcR的活化单核细胞-巨噬细胞,然后洗涤并与正常供体的活化外周血单核细胞(PBMC)共培养。通过培养上清液中p24抗原半定量测定评估的有效病毒感染,可评估血清的保护/增强活性。数据清楚地表明,env蛋白免疫个体的血清中存在保护而非增强活性。